3D Systems DDD
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$1.81M (12 inflow days, 8 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 29.9% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 26.23% to 25.57% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Pinnacle Associates, Ltd. | Mutual Fund | 2026/Q3 | +1,916,783 | 1.4% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +1,708,552 | 1.0% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +1,671,993 | 1.8% |
| LPL Financial LLC | Mutual Fund | 2026/Q3 | +1,508,546 | 1.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +955,788 | 8.7% |
| Aigh Capital Management, LLC | Hedge Fund | 2026/Q3 | +853,428 | 4.9% |
| Dimensional Fund Advisors | Mutual Fund | 2026/Q3 | +294,899 | 1.6% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +277,568 | 0.8% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +1,038,899 | 1.7% |
| Aigh Capital Management, LLC | Hedge Fund | 2026/Q3 | +7,271,000 | 4.4% |
| Needham Investment Management, LLC | Mutual Fund | 2026/Q3 | +3,525,200 | 2.1% |
| Medina Value Partners, LLC | Hedge Fund | 2026/Q3 | +3,279,375 | 2.0% |
| BlackRock | Mutual Fund | 2026/Q3 | +2,752,009 | 8.2% |
| Acadian Asset Management LLC | Mutual Fund | 2026/Q3 | +2,682,326 | 1.7% |
| Goldman Sachs Asset Management, L.P. | Mutual Fund | 2026/Q3 | +1,899,587 | 1.3% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 16 Sep 2026 | Jeffrey Graves | Chief Executive Officer | Open Market Disposition | -42,686 | $3.55 | 1,231,596 |
| 16 Sep 2026 | Phyllis Nordstrom | Executive VP, CFO & Chief Administrative Officer | Open Market Disposition | -30,000 | $3.58 | 715,871 |
| 7 Sep 2026 | Charles Hull | Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus | Sale to Issuer | -4,943 | $3.38 | 513,577 |
| 7 Sep 2026 | Jeffrey Graves | Chief Executive Officer | Sale to Issuer | -39,959 | $3.38 | 1,274,282 |
| 7 Sep 2026 | Phyllis Nordstrom | Executive VP, CFO & Chief Administrative Officer | Sale to Issuer | -47,396 | $3.38 | 745,871 |
| 7 Sep 2026 | Andrew Wright | Senior VP of General Counsel & Corporate Secretary | Sale to Issuer | -5,818 | $3.38 | 136,963 |
| 7 Sep 2026 | Reji Puthenveetil | Executive VP of Additive Solutions & Chief Commercial Officer | Sale to Issuer | -15,984 | $3.38 | 486,144 |
| 7 Sep 2026 | Joseph Zuiker | Executive Vice President of Engineering & Operations | Sale to Issuer | -6,689 | $3.38 | 271,362 |
| 19 Aug 2026 | Jeffrey Graves | Chief Executive Officer | Open Market Disposition | -115,500 | $3.26 | 1,314,241 |
| 13 May 2026 | Jim Kever | Independent Director | Other Acquisition | +45,731 | – | 560,650 |
| 13 May 2026 | Thomas Erickson | Independent Director | Other Acquisition | +45,731 | – | 395,178 |
| 13 May 2026 | Kevin Moore | Independent Director | Other Acquisition | +45,731 | – | 317,427 |
| 13 May 2026 | Charles McClure | Independent Chairperson | Other Acquisition | +45,731 | – | 227,848 |
| 13 May 2026 | John Tracy | Independent Director | Other Acquisition | +45,731 | – | 226,442 |
| 13 May 2026 | Malissia Clinton | Independent Director | Other Acquisition | +45,731 | – | 200,669 |
| 13 May 2026 | Vasant Padmanabhan | Independent Director | Other Acquisition | +45,731 | – | 192,915 |
| 13 May 2026 | Claudia Drayton | Independent Director | Other Acquisition | +45,731 | – | 174,369 |
| 13 Apr 2026 | Charles Hull | Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus | Sale to Issuer | -4,102 | $1.98 | 518,520 |
| 13 Apr 2026 | Jeffrey Graves | Chief Executive Officer | Sale to Issuer | -30,500 | $1.98 | 1,429,741 |
| 13 Apr 2026 | Phyllis Nordstrom | Executive VP, CFO & Chief Administrative Officer | Sale to Issuer | -1,626 | $1.98 | 793,267 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 42,482,339 | 25.6% | 19.5 |
| 15 Oct 2026 | 43,657,910 | 26.3% | 15.3 |
| 30 Sep 2026 | 43,767,924 | 26.3% | 17.2 |
| 15 Sep 2026 | 43,937,708 | 26.4% | 21.3 |
| 31 Aug 2026 | 43,721,595 | 26.3% | 22.7 |
| 14 Aug 2026 | 43,582,815 | 26.2% | 8.2 |
No comments yet — be the first to weigh in on DDD.
Sign in to join the discussion.